Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Cash from Operations (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Cash from Operations for 6 consecutive years, with 32251000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 31.73% to 32251000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 150024000.0 through Dec 2025, up 7.62% year-over-year, with the annual reading at 150024000.0 for FY2025, 7.62% up from the prior year.
  • Cash from Operations hit 32251000.0 in Q4 2025 for Lyell Immunopharma, down from 28577000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 25492000.0 in Q3 2021 to a low of 54738000.0 in Q1 2025.
  • Historically, Cash from Operations has averaged 38595800.0 across 5 years, with a median of 37890000.0 in 2023.
  • Biggest five-year swings in Cash from Operations: plummeted 45.55% in 2022 and later skyrocketed 31.73% in 2025.
  • Year by year, Cash from Operations stood at 33213000.0 in 2021, then decreased by 21.24% to 40267000.0 in 2022, then decreased by 0.91% to 40635000.0 in 2023, then dropped by 16.26% to 47242000.0 in 2024, then surged by 31.73% to 32251000.0 in 2025.
  • Business Quant data shows Cash from Operations for LYEL at 32251000.0 in Q4 2025, 28577000.0 in Q3 2025, and 34458000.0 in Q2 2025.